Last reviewed · How we verify
Budesonide Nasal
At a glance
| Generic name | Budesonide Nasal |
|---|---|
| Also known as | Experimental group, Rhinocort (commercial name for budesonide), intanasal corticosteroids, Busonid, Rhinocort |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (PHASE4)
- The Efficacy of Olfactory Cleft Steroid Drops in Patients With CRS With Olfactory Cleft Obstruction (NA)
- The Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With PIOD (NA)
- Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity (PHASE3)
- Nebulized Nasal Steroids (PHASE1, PHASE2)
- Efficacy of Buteyko Breathing in Seniors With Chronic Eustachian Tube Dysfunction (NA)
- Dupilumab in Chinese Adult Participants With CRSwNP (PHASE3)
- Nasal Obstruction With Oxymetazoline and Corticosteroids (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide Nasal CI brief — competitive landscape report
- Budesonide Nasal updates RSS · CI watch RSS
- Fondation Ophtalmologique Adolphe de Rothschild portfolio CI